Halkid

Halkid is a prescription medication that contains the active ingredient haloperidol, a butyrophenone antipsychotic, supplied in an oral dosage form. It is marketed in the European Union and is classified under the ATC code N05AD01. Haloperidol works as a dopamine D2 receptor antagonist and is used under medical supervision for certain psychiatric conditions. The product is intended for adult patients and should be prescribed by a healthcare professional after assessment.

Halkid (haloperidol) is indicated for the management of several psychiatric disorders where dopamine dysregulation is implicated.

- Schizophrenia, including acute exacerbations and maintenance therapy. - Acute psychotic episodes associated with mood disorders or substance use. - Manic episodes in bipolar disorder when rapid control of agitation is required. - Severe agitation or hostility in patients with dementia, when non‑pharmacologic measures are insufficient (off‑label in some regions). - Adjunctive treatment for Tourette syndrome or other hyperkinetic movement disorders (off‑label).

Haloperidol may cause a range of adverse effects that vary in frequency and severity, affecting multiple organ systems.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth, constipation, or blurred vision. - Weight gain or increased appetite. - Orthostatic hypotension, leading to dizziness upon standing. - Nausea or vomiting.

Serious: - Neuroleptic malignant syndrome, a life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia, characterized by involuntary, repetitive movements. - Cardiac arrhythmias, including QT prolongation. - Severe depression or suicidal thoughts. - Hepatic dysfunction indicated by elevated liver enzymes.

When prescribing Halkid, clinicians should consider several precautionary measures to minimize risks and ensure safe use.

- Assess for a history of cardiovascular disease, as haloperidol can prolong the QT interval. - Evaluate for prior movement disorders or extrapyramidal symptoms before initiating therapy. - Use caution in patients with hepatic or renal impairment; dose adjustments may be necessary. - Monitor for signs of neuroleptic malignant syndrome, especially during rapid dose escalation. - Avoid use in individuals with known hypersensitivity to haloperidol or other butyrophenones. - Consider pregnancy and lactation status; the drug’s safety profile in these populations is not well established.

Haloperidol can interact with other medications, potentially altering its efficacy or increasing adverse effects.

Avoid: - Other QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics) that may raise the risk of cardiac arrhythmias. - CNS depressants such as benzodiazepines or opioids, which can enhance sedation and respiratory depression. - Anticholinergic drugs that may mask extrapyramidal symptoms.

Use with caution: - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) which can increase haloperidol plasma levels. - CYP3A4 inducers (e.g., carbamazepine, rifampin) that may reduce therapeutic concentrations. - Lithium, as combined use may increase the risk of neurotoxicity.